Sugi Predict

Sugi Predict / Compounds / SCHEMBL403618

SCHEMBL403618

SCHEMBL403618

CS(=O)(=O)c1ccc(C(=O)O)c(Cl)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.74
▸ TSHR P16473 1/20 0.55
▸ CASP1 P29466 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.55
▸ AVPR2 P30518 1/20 0.51
▸ GPR27 Q9NS67 1/20 0.51
▸ ALDH1A1 P00352 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ PPARG P37231 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ NCOA2 Q15596 1/20 0.50
▸ NCOA1 Q15788 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ RXFP1 Q9HBX9 1/20 0.50
▸ MAPT P10636 4/20 0.49
▸ GAA P10253 1/20 0.49
▸ RAB9A P51151 1/20 0.49
▸ SMO Q99835 1/20 0.48
▸ MYC P01106 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9651756 0.98 LMNA (0.72) LMNATSHRCASP1SMN1; SMN2AVPR2
SCHEMBL1016807 0.85 LMNA (0.59) LMNAAVPR2GPR27ALDH1A1MEN1
SCHEMBL12724094 0.85 LMNA (0.59) LMNAAVPR2GPR27ALDH1A1MEN1
SCHEMBL34694 0.85 LMNA (1.00) LMNATSHRALDH1A1MEN1KMT2A
SCHEMBL2807663 0.85 TSHR (0.59) LMNATSHRCASP1SMN1; SMN2ALDH1A1
SCHEMBL2894517 0.84 LMNA (0.57) LMNAAVPR2GPR27ALDH1A1MEN1
SCHEMBL7527853 0.83 ALDH1A1 (0.58) LMNATSHRCASP1SMN1; SMN2ALDH1A1
SCHEMBL9516048 0.83 TSHR (0.57) LMNATSHRCASP1SMN1; SMN2ALDH1A1
SCHEMBL8962352 0.82 LMNA (0.70) LMNAALDH1A1MEN1KMT2A
SCHEMBL1017556 0.82 TSHR (0.52) LMNATSHRCASP1SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 398 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119859148-A Spiroteine framework compound and preparation method and application thereof 安徽农业大学 2025-04-22 — — CN claimed
US-20250107525-A1 CARBOXYLIC ACID-DERIVED KETO-DIESTERS AND USES THEREOF UNIVERSITY OF MISSISSIPPI 2025-04-03 — — US claimed
CN-119409682-A 1H-indazole compound and preparation method and application thereof 南京健康产业研究院 2025-02-11 — — CN claimed
CN-114213202-B Preparation method of 2, 4-substituted benzoic acid 石河子大学 2024-07-05 — — CN claimed
CN-118184679-A Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material 中国石油天然气股份有限公司 2024-06-14 — — CN claimed
CN-117886723-A Synthesis method of 2-chloro-4-methylsulfonyl benzoic acid 辽宁龙田化工科技有限公司 2024-04-16 — — CN claimed
CN-117263832-A Synthesis method of 2-chloro-4-methylsulfonyl benzoic acid 辽宁龙田化工科技有限公司 2023-12-22 — — CN claimed
CN-113735745-B Preparation method of 2-chloro-4-methylsulfonyl benzoic acid 武汉强丰新特科技有限公司 2023-05-09 — — CN claimed
CN-113880762-B Triacylamine derivatives containing 1,8-naphthalimide as well as preparation method and application thereof 河北农业大学 2023-02-21 — — CN claimed
CN-114213202-A Preparation method of 2, 4-substituted benzoic acid 石河子大学 2022-03-22 — — CN claimed
CN-113603626-A Preparation method of free radical initiator and application of free radical initiator in oxidation reaction 武汉强丰新特科技有限公司 2021-11-05 — — CN claimed
US-9278932-B1 Process for preparation of 2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide solid forms SHILPA MEDICARE LIMITED (IN) 2016-03-08 — — US claimed
US-20160060220-A1 PROCESS FOR PREPARATION OF 2-CHLORO-N-(4-CHLORO-3-PYRIDIN-2-YLPHENYL)-4-METHYLSULFONYLBENZAMIDE SOLID FORMS SHILPA MEDICARE LIMITED (IN) 2016-03-03 — — US claimed
EP-2976326-A2 PROCESS FOR PREPARATION OF 2-CHLORO-N-(4-CHLORO-3-PYRIDIN-2-YLPHENYL)-4-METHYLSULFONYLBENZAMIDE SOLID FORMS Shilpa Medicare Limited (IN) 2016-01-27 — — EP claimed
WO-2014147504-A2 PROCESS FOR PREPARATION OF 2-CHLORO-N-(4-CHLORO-3-PYRIDIN-2-YLPHENYL)-4-METHYLSULFONYLBENZAMIDE SOLID FORMS SHILPA MEDICARE LIMITED (IN) 2014-09-25 — — WO claimed
CN-1732161-A 1,3-diamino-2-hydroxypropane pro-drug derivatives ELAN PHARM INC (US) 2006-02-08 — — CN claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 — — EP claimed
EP-0700379-B1 PROCESS TO PREPARE P-ALKYL- AND P-ARYLSULPHONYLBENZOIC ACID DERIVATIVES ZENECA LTD (GB) 1998-01-07 — — EP claimed
EP-0700379-A1 PROCESS TO PREPARE P-ALKYL- AND P-ARYLSULPHONYLBENZOIC ACID DERIVATIVES ZENECA LIMITED (GB) 1996-03-13 — — EP claimed
WO-1994027959-A1 PROCESS TO PREPARE P-ALKYL- AND P-ARYLSULPHONYLBENZOIC ACID DERIVATIVES ZENECA LIMITED (GB) 1994-12-08 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250107525-A1 CARBOXYLIC ACID-DERIVED KETO-DIESTERS AND USES THEREOF BCKDK, KYAT1, KYAT3 LMNA 4553/4885TSHR 3324/4885CASP1 1511/4885
US-20160060220-A1 PROCESS FOR PREPARATION OF 2-CHLORO-N-(4-CHLORO-3-PYRIDIN-2-YLPHENYL)-4-METHYLSULFONYLBENZAMIDE SOLID FORMS SKP1, CYP2S1, KDM4A LMNA 913/4885TSHR 4489/4885CASP1 1441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.